Search: onr:"swepub:oai:DiVA.org:liu-21807" >
Treatment of malign...
Treatment of malignant pleural mesothelioma with liposomized doxorubicine : prolonged time to progression and good survival. A Nordic study
-
- Hillerdal, Gunnar (author)
- Karolinska Institutet
-
- Benn Sorensen, Jens (author)
- Finsen Institute, Department of Oncology, National University Hospital/Finsen Institute, Copenhagen, Denmark
-
- Sundström, Stein (author)
- Regional Hospital, Trondheim, Norway
-
show more...
-
- Vikström, Anders (author)
- Linköpings universitet,Östergötlands Läns Landsting,Lungmedicinska kliniken US,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet
-
- Hjerpe, A (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2008
- 2008
- English.
-
In: The Clinical Respiratory Journal. - 1752-6981 .- 1752-699X. ; 2:2, s. 80-85
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Introduction: Malignant pleural mesothelioma (MPM) has a poor prognosis and there is limited effect of treatment. Lately, pemetrexed and cisplatin have been established as the standard treatment. Objectives: The present study was planned in 1998, when there was no standard treatment. Single-dose doxorubicine had, in small studies, accomplished remissions, and the Scandinavian Mesothelioma Groups therefore decided to test a liposomized form of this drug, which had shown limited toxicity but good efficacy in a few small studies. Methods: Fifty-four evaluable patients with histologically verified and inoperable MPM were treated with liposomized doxorubicine 40 mg/m2, every 4 weeks for six cycles. Results: In all, 29 patients (54%) received at least six treatments. The quality of life remained good during the study. Hematologic toxicity was very low. Palmo–plantar erythema occurred in 11 patients (20%), thereof 7 grade II but none was severe and none was dose-limiting. There were four partial responses (7%). The median time to progression (TTP) was 5 months, the median survival was 12 months, and at 24 months, 22% were still alive. Conclusion: Liposomized doxorubicine has a low toxicity and is well tolerated; there were a remarkably long TTP and a good survival. Thus, despite the low response rate, liposomized doxorubicine remains an interesting drug for the treatment of malignant mesothelioma.
Keyword
- liposomized doxorubicine - mesothelioma - phase II study - treatment
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database